Infective endocarditis; Valve surgery; Endocarditis-Team; Multidisciplinary management; 18 F-FDG PET/CT; Embolic events 12 Ruch Y., Mazzucotelli J.P., Lefebvre F., et ...

However, description of its efficacy in the setting of vegetation size stratification has remained sparse. We present our unique experience with the AngioVac system in patients with tricuspid valve ...

However, description of gender-related outcomes and analysis has remained sparse. We present our unique experience with the AngioVac system in men compared to women with tricuspid valve infective ...

TUESDAY, Nov. 5, 2024 (HealthDay News) — For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement (TTVR) plus optimal medical therapy ...

The researchers found that the primary end point (hierarchical composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations [HFH], and quality-of-life improvement ...

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement (TTVR) plus optimal medical therapy (OMT) yields substantial improvement ...

TRAVEL II aims to evaluate the long-term safety and efficacy of LuX-Valve Plus in the application on patients with severe tricuspid regurgitation and high surgical risk. The clinical trial enrolled 96 ...

TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to ...

TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. In this international, multicenter trial, we randomly assigned 400 patients with severe symptomatic ...